Pharmacokinetic Data

All commercially insured patients new to Trokendi XR pay nothing for a minimum of 12 prescriptions*—guaranteed.

*Click here for Terms and Conditions.

Trokendi XR® (topiramate) delivers the efficacy you’d expect with QD dosing for steady, 24-hour migraine medication coverage1, 2

Chart showing that once-daily Trokendi XR® (topiramate) is bioequivalent to twice-daily Topamax® (topiramate)

Watch Video

  • Fluctuation in plasma concentration of QD Trokendi XR was ~26% for healthy subjects compared to ~40% for subjects taking TPM-IR1,2 

Study design1

  • A phase 1, single-center, multiple-dose, single-blind, randomized, crossover, pharmacokinetic (PK) study of Trokendi XR (topiramate) (200 mg once daily) and Topamax (topiramate) (100 mg twice daily) in 39 healthy adults
  • Subjects were titrated to a 200 mg/day dose of either Trokendi XR (topiramate) or Topamax (topiramate) over a period of 3 weeks
  • Following titration, subjects were maintained on 200 mg/day for 10 days
  • Following a 32-day washout period, subjects crossed over to alternate treatment

Primary endpoint1

  • Relative bioavailability of Trokendi XR (topiramate) and Topamax (topiramate) at steady-state

Once-daily Trokendi XR (topiramate) was designed and approved to be written QD2

Chart showing Trokendi XR® (topiramate) vs QD TPM-IR during a 72-hour time frame Abbreviations: AED, antiepileptic drug; CI, confidence interval; PK, pharmacokinetic; SS, steady state; TPM-IR, immediate-release topiramate.

Watch Video

Immediate-release topiramate was not designed or approved to be prescribed QD2,3

What role can patient preference play in migraine therapy?

Once-daily Trokendi XR (topiramate) is the #1-branded migraine prevention treatment1

Learn how Microtrol® technology works to help maintain 24-hour migraine prevention coverage

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS & PRECAUTIONS

DOSING GUIDELINES & CONSIDERATIONS

ADVERSE REACTIONS

 

INDICATION

Please refer to the full Prescribing Information and Medication Guide for additional important information on Trokendi XR.

Trokendi XR (topiramate) extended-release capsules

 

REFERENCES:

  1. Data on file. Supernus Pharmaceuticals, Inc., Rockville, MD.
  2. Trokendi XR [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; January 2018.
  3. Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; June 2018.
  4. Brittain ST, Wheless JW. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs immediate-release formulations. Epilepsy Behav. 2015;52:31-36.